Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | POLG | P54098 | 2/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257977 | 0.92 | POLB (0.56) | POLBPOLGP2RY2P2RY4P2RY6 | |
| SCHEMBL4254628 | 0.90 | POLG (0.57) | POLBPOLGP2RY2P2RY4P2RY6 | |
| SCHEMBL350551 | 0.84 | POLB (0.50) | POLBPOLGP2RY2P2RY4P2RY6 | |
| Hydrochloric Acid SCHEMBL19555528 | 0.83 | POLB (0.49) | POLBPOLGP2RY2P2RY4P2RY6 | |
| SCHEMBL4267963 | 0.78 | DUT (0.52) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6534196 | 0.78 | POLB (0.47) | POLBPOLGP2RY2P2RY4P2RY6 | |
| SCHEMBL3485775 | 0.77 | POLB (0.52) | POLBPOLGP2RY2P2RY4P2RY6 | |
| SCHEMBL7636345 | 0.77 | POLG (0.57) | POLBPOLGP2RY2P2RY4P2RY6 | |
| SCHEMBL23751346 | 0.76 | POLB (0.80) | POLBPOLGP2RY2P2RY4P2RY6 | |
| SCHEMBL12595477 | 0.76 | POLB (0.80) | POLBPOLGP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114306240-A | Gemcitabine or liposome of salt thereof, preparation method and application thereof | 四川科伦药物研究院有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20160324885-A1 | COMPOSITION CONTAINING MODIFIED DERIVATIVES OF A CYTIDINE ANTIMETABOLITE FOR THE TREATMENT OF SUSCEPTIBLE DISEASE | ASTERIAPHARMA GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| EP-2854864-B1 | COMPOSITIONS COMPRISING OLIGOMERS OF GEMCITABINE FOR USE IN THERAPY | ASTERIAPHARMA GMBH (DE) | 2016-05-04 | — | — | EP | disclosed |
| EP-2854864-A1 | COMPOSITION CONTAINING MODIFIED DERIVATIVES OF A CYTIDINE ANTIMETABOLITE FOR THE TREATMENT OF SUSCEPTIBLE DISEASE | Asteriapharma GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
| WO-2015003747-A1 | COMPOSITION CONTAINING MODIFIED DERIVATIVES OF A CYTIDINE ANTIMETABOLITE FOR THE TREATMENT OF SUSCEPTIBLE DISEASE | ASTERIAPHARMA GMBH (DE) | 2015-01-15 | — | — | WO | disclosed |
| US-8388966-B2 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100311606-A1 | PHARMACOGENOMIC CELL LINE PANEL AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-09 | — | — | US | disclosed |
| US-20090004200-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2008137907-A1 | PHARMACOGENOMIC CELL LINE PANEL AND USE THEREOF | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20060140962-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1372717-A2 | COMBINATION TREATMENT OF PANCREATIC CANCER | APHTON CORPORATION (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030091574-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002076499-A2 | COMBINATION TREATMENT OF PANCREATIC CANCER | APHTON CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324885-A1 | COMPOSITION CONTAINING MODIFIED DERIVATIVES OF A CYTIDINE ANTIMETABOLITE FOR THE TREATMENT OF SUSCEPTIBLE DISEASE | DCTD, TYMP, CDA | POLB 125/4885POLG 104/4885P2RY2 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.